Cover Image
市場調查報告書

市場預測自體免疫溶血性貧血 (AIHA)的主要8個國家

Autoimmune Haemolytic Anaemia (AIHA) in 8 Major Markets 2016-2026

出版商 Black Swan Analysis 商品編碼 363599
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
市場預測自體免疫溶血性貧血 (AIHA)的主要8個國家 Autoimmune Haemolytic Anaemia (AIHA) in 8 Major Markets 2016-2026
出版日期: 2016年07月20日 內容資訊: 英文 48 Pages
簡介

本報告提供全球主要8個國家(美國、法國、德國、義大利、西班牙、英國、巴西、日本) 的自體免疫溶血性貧血 (AIHA)的目前患者數 (性別,各年齡世代) 的調查分析,目前盛行率,加上疾病概要,危險因素,疾病診斷預後,主要的提供著症狀和併發症等系統性資訊。

簡介

病因

危險因素和預防

疾病診斷

變異:各地區/民族

疾病預後和臨床過程

AIHA臨床管理

  • AIHA的輸血療法

疾病相關的主要併發症/特徵

定量化做患者數的手法

自體免疫溶血性貧血 (AIHA)的最大患病人數

自體免疫溶血性貧血 (AIHA) 患者的亞型

  • 溫式自體免疫溶血性貧血 (AIHA) 患者
  • 冷式自體免疫溶血性貧血 (AIHA) 患者
  • 混合式自體免疫溶血性貧血 (AIHA) 患者

自體免疫溶血性貧血 (AIHA)的市場預測

  • 溫式、混合式AIHA中的第一治療選項
  • 溫式、混合式AIHA的第二治療選項
  • 冷式AIHA中的第一治療選項
  • 冷式AIHA的第二治療選項
  • AIHA的輸血的必要條件

預測的調查手法 圖表

簡稱

相關出版

病患人數的線上資料庫

病患人數的產品

價格的線上資料、平台

參考文獻

附錄

圖表

目錄
Product Code: AIHA0010716

image1

Autoimmune haemolytic anaemia (AIHA) is an immune disorder caused by auto-antibodies against unmodified autologous red blood cells and can range in presentation from a mild illness to a rapidly fatal severe condition.

This report provides the current incident population for AIHA across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of AIHA's have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for AIHA include:

  • Lymphoproliferative conditions:
    • CLL
    • HL
    • NHL
  • Myeloproliferative conditions:
    • Multiple myeloma
    • Myelofibrosis
    • MGUS
  • Autoimmune conditions:
    • RA
    • SLE
    • Polyarteritis nodosa
  • Infections:
    • Pneumonia & Tuberculosis
    • Syphilis
    • Epstein-Barr
    • Chronic active hepatitis
    • Mononucleosis

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global AIHA's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the incidence of the subdivided types of AIHA and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on AIHA's incident population.
  • Identify sub-populations within AIHA which require treatment.
  • Gain an understanding of the specific markets that have the largest number of AIHA patients.

Coverage

BR, FR, DE, IT, JP, ES, UK, US

image2

Table of Contents

List of Tables and Figures

Introduction

Cause of the Disease

Risk Factors & Prevention

Diagnosis of the Disease

Variation by Geography/Ethnicity

Disease Prognosis & Clinical Course

Clinical Management of AIHA

Transfusion therapy in AIHA

Key Co-morbid Conditions/Features Associated with the Disease

Methodology for Quantification of Patient Numbers

Top-Line Incidence for AIHA

Subtypes of AIHA patients

  • Warm AIHA patients
  • Cold AIHA patients
  • Mixed-type AIHA patients

Market Forecast for AIHA

  • 1st Line Treatment Options within Warm & Mixed-type AIHA
  • 2nd Line Treatment Options within Warm & Mixed-type AIHA
  • 1st Line Treatment Options within Cold AIHA
  • 2nd Line Treatment Options within Cold AIHA
  • Requirement for Blood Transfusions within AIHA

Methodology for Forecast Figures

Abbreviations used in the report

Other Black Swan Analysis Publications

Black Swan Analysis Online Patient-Based Databases

Patient-Based Offering

Online Pricing Data and Platforms

References

Appendix

List of Tables

  • Drugs implicated in development of AIHA
  • Tests for AIHA and expected findings in haemolysis
  • Classification of AIHA
  • Treatment options for warm AIHA
  • Treatment options for cold AIHA
  • Incidence of AIHA, total (000s)
  • Incidence of AIHA, males (000s)
  • Incidence of AIHA, females (000s)
  • Incident AIHA by main sub-type, total (000s)
  • Incident Warm AIHA by cause, total (000s)
  • Warm Secondary AIHA by main aetiology, total (000s)
  • Incident Cold AIHA by main type, total (000s)
  • Incident CAS AIHA by cause, total (000s)
  • CAS Secondary AIHA by main aetiology, total (000s)
  • Incident Mixed-type AIHA by cause, total (000s)
  • Mixed-type Secondary AIHA by main aetiology, total (000s)
  • Prednisolone estimated forecast 1st line, Revenue (£000s)
  • Rituximab estimated forecast 2nd line, Revenue (£000s)
  • Splenectomy estimated forecast 2nd line, Patients (000s)
  • Rituximab estimated forecast 1st line, Revenue (£000s)
  • Rituximab estimated forecast 2nd line, Revenue (£000s)
  • Transfusion estimated forecast, Patients (000s)
  • Abbreviations and Acronyms used in the report
  • USA Incidence of AIHA by 5-yr age cohort, males (000s)
  • USA Incidence of AIHA by 5-yr age cohort, females (000s)
  • France Incidence of AIHA by 5-yr age cohort, males (000s)
  • France Incidence of AIHA by 5-yr age cohort, females (000s)
  • Germany Incidence of AIHA by 5-yr age cohort, males (000s)
  • Germany Incidence of AIHA by 5-yr age cohort, females (000s)
  • Italy Incidence of AIHA by 5-yr age cohort, males (000s)
  • Italy Incidence of AIHA by 5-yr age cohort, females (000s)
  • Spain Incidence of AIHA by 5-yr age cohort, males (000s)
  • Spain Incidence of AIHA by 5-yr age cohort, females (000s)
  • UK Incidence of AIHA by 5-yr age cohort, males (000s)
  • UK Incidence of AIHA by 5-yr age cohort, females (000s)
  • Brazil Incidence of AIHA by 5-yr age cohort, males (000s)
  • Brazil Incidence of AIHA by 5-yr age cohort, females (000s)
  • Japan Incidence of AIHA by 5-yr age cohort, males (000s)
  • Japan Incidence of AIHA by 5-yr age cohort, females (000s)
Back to Top